CARE BENZORGANICS PVT LTD
COMPANY SUMMARY
 Company was founded in the year 2001 and deals in




marketing of pharmaceutical products by own brand
names with registered trade marks.
Presently operating in four states- Andhra Pradesh;
Maharashtra; Odisha & Rajasthan.
Current revenue Rs 18 lakh per month.
Plans to expand operations in ten states with product
range in anti-diabetic segment.
Indian pharma market is estimated at Rs 79500cr &
growing @ 7s% per annum; in terms of volume- the third
largest in the world after USA & Japan.
FOUNDERS DETAILS




S.G.Kulkarni (Msc-tech chemistry) - DIRECTOR – FOUNDER
SHARE HOLDING – 25%
After completing post-graduation from JNTU Hyderabad (1996)
started career in sales with Systopic laboratories & then Lupin
labs till yr 2000 & thereafter embarked upon his journey as an
entrepreneur by founding this company.
Successfully launched the company in Andhra Pradesh in the
yr 2001; Maharashtra in yr 2011; Rajasthan in yr 2014 & presently
overlooking sales in these states yielding good revenue flow.
Responsible for product management i.e. Brand positioning ;
Branding ; product portfolio management; product training etc.
Now has set a vision for the company to aim for Pan-India
operations with new product range in anti-diabetic segmentpresently estimated at Rs 5000cr and growing @ 22% per annum.
FOUNDERS DETAILS




Manas Ranjan Sahu (Bsc MPC)- DIRECTOR – FOUNDER
SHARE HOLDING – 25%
After completion of graduation (1996) started his carrier in
sales with Emcure Pharmaceuticals and then Lupin Labs
till year 2000 thereafter co-founded this Company to
embark on his journey to entrepreneur ship.
Successfully launched the company in Andhra Pradesh in
the year 2001 and Odisha in 2012 generating continuous
revenue base.
The capability to spontaneously make friends and connect
with people helps in building good rapport with customers
employees etc, and can go a great length in building a great
team imperatively required for pan India expansion.
FOUNDERS DETAILS
 T.K.Shankar rao (Bsc MPC)-Founder member
 SHARE HOLDING – 25%
 Served as one of the director in the company since the
inception till march 2013 & resigned from service due
to health issues.
 At present serving the company as GM admin to assist
in business expansion process.
FOUNDERS DETAILS
 C.Narendra Babu (BA & diploma in Marketing )



Founder Member.
SHARE HOLDING – 25%
Served as one of the director .
Resigned as director in march 2011 due to personal
reasons.
Presently serving in the company as in charge for
Rayalseema region since April 2014 & plans to expand
operations in south India.
MARKET OPPORTUNITY
SEGMENTS
PRESENT SIZE & GROWTH RATE
INDIAN PHARMA MARKET
Rs 79500 Cr - 7% per annum
ANTI - INFECTIVE
Rs 10000 Cr - 20% per annum
ANALGESIC
Rs 3000 Cr - 20% per annum
CALCIUM + CALCITRIOL
Rs 6000 Cr - 11.7% per annum
PPI ( ANTI – ULCERANT )
Rs 1000 Cr
ANTI – DIABETIC
Rs 5000 Cr - 11% per annum
- 14% per annum
Present product Range
PRODUCT NAME
COMPOSITION
SEGMENT
SERRATIOPEPTIDASE
ANTI-INFLAMMATORYANALGESIC
RESOLVE® – D(TABLET)
SERRATIOPEPTIDASE +
DICLOFENAC SODIUM
ANTI-INFLAMMATORYANALGESIC
RESOLVE® –AP(TABLET)
SERRATIOPEPTIDASE
+ACECLOFENAC
+PARACETAMOL
ANTIINFLAMMATORYANALGESIC
OSIPHILE®
CALCIUM +
CALCITRIOL
CALCIUM SUPPLEMENT
ANALOG™ –P (TABLET)
TRAMADOL +
PARACETAMOL
ANTI-INFLAMMATORYANALGESIC
CF3-O ™
CEFUROXIME AXETIL
ANTI INFECTIVE
RESOLVE®
(TABLET)
(TABLET)
( TABLET)
Present Product Range
PRODUCT NAME
COMPOSITION
SEGMENT
FEREAL ™
(TABLET) FERROUS ASCORBATE + HAEMATINIC
FOLIC ACID
HAVITAL®
(TABLET) MULTIVITAMIN +
ANTIOXIDANT+MULTI
MINERALS
RABESTIME™ (TABLET)
RABESTIME-DSR (CAP)
CISCAP ™
RABEPRAZOLE
+DOMPERIDONE
(CAPSULE) AYURVEDIC (CISSUS
QUADRANGULARIS
LINN EXTRACT)
SUPPLEMENT
PPI (ANTI – ULCERANT)
ORTHOPAEDIC –
ENHANCES FRACTURE
HEALING PROCESS.
NEW LAUNCHES - 2014
PRODUCT NAME
COMPOSITION
SEGMENT
RELAXID-MR 4
ACECLOFENAC+THIOC
OLCHICOSIDE4mg+PARACETAMOL
NEW GENERATION
MUSCLE RELAXANT
ORTHOPAEDIC
RELAXID-MR 8
ACECLOFENAC+THIOC
OLCHICOSIDE8mg+PARACETAMOL
NEW GENERATION
MUSCLE RELAXANT
ORTHOPAEDIC
HAVITAL PLUS
ALPHA LIPOIC
ACID+METHYLCOBALA
MINE+PYRIDOXINE+FO
LIC ACID
IN DIABETIC
NEUROPATHY- ANTI
DIABETIC SEGMENT
Revenues for previous 4 years
YEAR
TURNOVER
PROFIT BEFORE TAX
Yr 2013 - 2014
Rs 16250659.00
Rs1235000.00
Yr 2012 - 2013
Rs 14254328.00
Rs 941933.00
Yr 2011 - 2012
Rs 11175978.00
Rs 715962.00
Yr 2010 - 2011
Rs 10992118.00
Rs 731736.00
Year V/S Revenues in Cr.
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
2010-2011
2011-2012
2012-2013
2013-2014
Competitive Landscape
 Indian pharma market is a highly fragmented market
but very huge in size & the third largest in the World
estimated at Rs 79500cr.
 Presently there are 24 thousand companies in this
industry marketing generic products with none of
them having any patent product.
 Top 10 companies hold almost 33% market share.
 The competition commission of India denies the
monopoly product to any company keeping in view the
demographic conditions in India & the Supreme
courts verdict against novartis is a case in point.
Competitive Landscape
 In pharma industry products are endorsed by the
doctors.
 Products therapeutic efficacy & good personal
relations with the customers plays a dominant role to
gain their loyalty towards the company.
 Participation in Continuous medical education (CME)
conferences is yet another key factor to keep them
engage with the company.
 Our growth rate is the prima-facie evidence to the
claim that as a company we have gained this niche.
Business proliferation pattern with Anti – Diabetic range
 The greatest advantage in operating with anti –diabetic
range is that the end consumer .i.e. patient stays with the
brand once his/ her blood glucose level is stabilized .The
brand becomes the part of his/ her life.
 Assuming that a Diabetologist or physician stabilizes 15
new patients per month on our brand & our target shall be
to have at least 5 such loyal doctors in each territory.
 Company plans to operate in 64 territories with 64 sales
executives across 10 states post investment.
Business proliferation pattern with Anti – Diabetic
range
 According to this assumption a doctor stabilizes 15
patients per month on our brand each patient
consuming 3 strips per month ;with 5 such doctors in
each territory & 64 territories under operation;
assuming Rs 38 per strip as price to stockiest ; the
number of end consumers at the end of first year;
second & third year & the stable revenue base would
be as shown below.
 First year-end - consumer base - 57600 patients.

revenue base - Rs 6566 400 per month.
Business proliferation pattern with Anti – Diabetic
range
 Second year-end – consumer base – 115200 patients

revenue base - Rs 1.31 Cr per month
 Third year-end - consumer base -172800 patients

revenue base – Rs 1.96 Cr per month.
 The above mentioned revenue base is for anti-diabetic
product range & revenues from existing product range
would be an additive factor.
Financial Projections in Cr.
FIRST YEAR
SECOND YEAR
THIRD YEAR
REVENUE
Rs 8.16 Cr
Rs 15.12 Cr
Rs 24.04 Cr
GROSS MARGIN
Rs 5.71 Cr
Rs 10.58 Cr
Rs 16.82 Cr
WORKING
CAPITAL
Rs 6.932Cr
Rs 11.97 Cr
Rs 18.48 Cr
EBIDTA
Rs 1.227 Cr – 15%
Rs 3.04 Cr – 20%
Rs 5.55 Cr -23%
Working capital requirement
Expenses Heads
Amount in rupees per annum
Salaries expenses
Rs 13260000.00
Production cost
Rs 24480000.00
Business promotion
Rs 16320000.00
Directors x 2
Rs 4800000.00
Administration & sundry expenses
Rs 7200000.00
Total working capital requirement
Rs 69324000.00 ( 6.93 Cr).
COMPANY VALUATION
 Company valuation: With reference to the deals
happening in pharma industry usually companies are
valued based on 5 to 10 times of their annual revenues.
 Valuation is on the higher side for the companies
having products in the chronic segment e.g. antidiabetic ,anti- hypertensive etc.
 Our focus shall be on anti-diabetic segment.
 Our expected valuation shall be between 6 to 9 times
of our annual revenues after 5 yrs from the date of
investment.
EXIT OPTION
 The descent exit shall arrive after fifth year by this time
our annual revenues should be in the range of 40 to 50
crores.
 This should be the ideal time for second round of
investment the proceeds to be invested for state of art
manufacturing facility-backward integration.
 Assuming our companys valuation to a bear minimum
of 6 times of revenues the valuation should arrive at a
minimum of 250cr through private equity route or a
VC with a greater investment appitite.

Come Invest in Care Benzorganics
and
Become part of a great Growth
Story.